Vote-by-mail form

the Ordinary General Meeting of Shareholders of Antibiotice S.A. held on 30.09/01.10.2026

The undersigned ______________________________ [*individual shareholder's* full name], identified by _______ [*identity card*], series ______, number _____________________, issued by ___________, on _____________, domiciled in ____, National Identification Number _____________________,

or

The undersigned____ [*name of the entity/legal person]*, established in ____________________________, registered at the Trade Register Office under no. J______________________ Unique Registration Code__________________, legally represented by ____ (*)

shareholder on the reference Date, i.e. **17.09.2026**, of Antibiotice S.A., a trading company registered at the Trade Register Office under number J1991000285223, fiscal code 1973096, holding a number of ____________shares, representing_________% of the total **671,338,040** shares issued by the Company, which grant me _______________ voting rights in the General Meeting of Shareholders representing ___________% of the total voting rights,

being aware of the Agenda for the Ordinary General Meeting of the Shareholders *Antibiotice S.A.* convened on **30.09.2026**, at 10:00 am**,** and respectively on **01.10.2026**, at 10:00 am (in the event that the conditions for organizing the General Meeting of Shareholders will not be met on the first above-mentioned date) and being aware of the documentation provided by *Antibiotice* SA in connection with these agendas,

and in accordance with Article 208 of the ASF Regulation no. 5/2018, I hereby exercise my right to vote by mail, as follows:

No	**Agenda for the Ordinary General Meeting of Shareholders**	**Option**		
		for	against	abstention
0	1	2	3	4
1.	The approval of the Financial Report for the first half of 2026, consisting of: a. simplified half-yearly financial statements; b. half-yearly report of the board of directors; c. the declaration of the responsible persons; d. the full report of the audit firm.			
2.	Approval of the allocation of 50% of the net profit for the 2025 financial year, setting the gross dividend at RON 0.019877174 per share, setting 16 October 2026 as the record date for identifying the shareholders entitled to the effects of this resolution, setting 15 October 2026 as the ex-date, and setting 28 October 2026 as the dividend payment commencement date.			

3.	Approval of the allocation of 90% of the net profit for the 2025 financial year, setting the gross dividend at RON 0.035778913 per share, setting 16 October 2026 as the record date for identifying the shareholders entitled to the effects of this resolution, setting 15 October 2026 as the ex-date, and setting 28 October 2026 as the dividend payment commencement date.			
4.	The ratification of the Management Board's Decision no. 1 of 25.06.2026, regarding: • the approval of the increase in the multicurrency, multiproduct, cash and non-cash credit facility, contracted with UniCredit Bank SA from the amount of RON 91,500,000 to the amount of RON 141,000,000. • the approval/maintenance of the guarantee of the facility mentioned above, in the amount of RON 141,000,000, which will be contracted with UniCredit Bank SA with the following: - Mortgage on the current and future accounts opened by Antibiotice SA at UniCredit Bank SA. • approval of the authorization of Mr. Ioan Nani as General Director to sign on behalf of Antibiotice SA all documents/credit contracts and their accessories, necessary and related to the contracting and implementation of the credit facility in the total amount of RON 141,000,000 from UniCredit Bank SA, as well as all the subsequent additional documents related to the documents/credit contracts and accessories related to this credit.			
5.	The rectification of the Decision no. 3 of the Ordinary General Meeting of Shareholders dated 06.11.2025, in order to remedy a material error, as follows: Resolution No. 3 of the Ordinary General Meeting of Shareholders dated November 6, 2025—stating "With the votes 'for' from shareholders representing 100% of the total votes cast, the vacancy of a director position at Antibiotice S.A. is acknowledged"—is rectified to read: "With the votes 'for' from shareholders representing 100% of the total votes cast, the vacancy of the director position held by Mr. Cătălin-Codruț Popescu is acknowledged, effective as of November 6, 2025."			

I hereby attach:

- Certified copy of the shareholder's ID – for individual shareholders (Identity card/passport/residence permit);
- Copy of the registration certificate for the legal persons/entities;
- Certified copy of the ID with respect to authorized agents/ attorneys-in-fact who are individuals (Identity card/passport/residence permit), if applicable;
- Special Power of Attorney for the agent/attorney-in-fact, in original (if applicable),
- The certificate of incorporation or any other document attesting to the quality of legal representative, in the case of legal entity shareholders.

Contact phone number____

I/The undersigned, am fully and exclusively liable for the stipulations contained therein, in my capacity as shareholder of Antibiotice trading company.

Date ____________

Individual shareholder

____
(Full name of the shareholder - in capitals)

____

(Shareholder’s signature)

Corporate shareholder

____
(Name of the shareholder – in capitals)

____

(Full name and position of the shareholder’s legal representative - in capitals)

____

(*Seal and signature* of the shareholder’s legal representative*)*

Contact phone no. ____________________

Note:
(*) to be completed for entities/corporate shareholders only.
The voting form by mail will be modified and completed accordingly if, in accordance with the legislation in force, one or more shareholders representing, individually or together, at least 5% of the share capital will introduce new items on the agenda of the general meeting.
In the event of updating the Vote-by-mail form, please check the requirements in the GM Convening Notice starting with the 16th day after the publication of the Convening Notice.
After filling in and signing the Vote by mail, an original copy shall be submitted/sent to Antibiotice headquarters, in a sealed envelope, mentioning the confidential nature of the content, so that it is recorded at the Antibiotice Registrar’s Office by 28.09.2026, 10:00 am at the latest.